

Management Buy-Out of Pan-European Pharmaceutical and Medical Devices Business

Corbett Keeling is pleased to announce that the management team of Speciality European Pharma Limited (“SEP” or “the Company”), has acquired the Company from its venture capital shareholders, with the backing of Juno Pharmaceuticals Inc. (“Juno”), an international speciality pharmaceutical company and leading life science investor.

Headquartered in the UK, SEP is a speciality pharmaceutical and medical devices group that focuses on meeting the needs of the specialist physician. The Company was founded in 2006 and has grown rapidly over the past five years, with a commercial presence in much of Europe and a desire to grow beyond. The transaction provides the Company with the opportunity not only to continue its growth strategy with the existing products but also to invest for the long-term in the untapped potential in its proprietary development portfolio.

The team at Corbett Keeling, led by Jim Keeling and Harry Knight, advised the management team on the buy-out, which completed in May 2016. The management team has a significant minority shareholding in the new business and an investor committed to driving the business forwards.

Commenting on Corbett Keeling, Patrick Banks, Chief Executive Officer of SEP, said:

“Corbett Keeling created a way forward, where others could not, at a critical moment for the management team. Their access to the appropriate funders in the UK and overseas, and their ability to move quickly, were both crucial to making this transaction possible.”

Commenting on the Management Buy-Out, Jim Keeling, Chairman of Corbett Keeling, said:

“Following the buy-out of SEP, the management team is extremely well placed to grow the business and realise the potential of its product portfolio. Together with backers, Juno, we wish them a successful future partnership.”

About Corbett Keeling

Corbett Keeling is an established corporate finance firm with a track record of over 20 years providing the services it continues to deliver today: advising management teams on buy-outs and buy-ins, guiding owners through the process of selling their businesses and providing specialist corporate finance advice.

Corbett Keeling operates in conjunction with a team of industry experts and international partners to provide both sector specialist advice and global reach. This approach is designed to ensure our clients receive the best possible advice and stand the best chance of achieving the optimal outcome for them and their businesses.

For more information on Corbett Keeling please visit www.corbettkeeling.com or contact Jim Keeling on +44 (0)20 7626 6266.

E: info@corbettkeeling.com
T: +44 (0)20 7626 6266
A: 8 Angel Court London EC2R 7HP United Kingdom

- **Selling businesses**
- **Management buy-outs**
- **Specialist advice**

About SEP

SEP is the parent company of a group which specialises in the distribution and sale of pharmaceutical products and medical devices, focused primarily upon the fields of urology and urogynaecology. Its marketed products are:

- Bulkamid®
- Aquamid®
- Mitem®
- Cystistat®

The Company was founded in 2006 and has built an experienced and accomplished management team, with established sales and marketing infrastructure in the leading European markets. It has offices in the UK, Denmark, Germany and France, with specialist distributor partners across the world. The Company employs 45 staff throughout Europe.

SEP also has portfolio of development/approval opportunities for new products derived from its proprietary polyacrylamide gel technology. These opportunities include:

- Bulkamid® approval in the United States
- Arthrosamid®, a synovial implant for osteoarthritis, currently undergoing regulatory approval in the EU
- Rectamid® for faecal incontinence in clinical development

About Juno

Juno Pharmaceuticals Inc. is an international speciality pharmaceutical company with operations in Canada, Australia, South Africa and Europe. Juno works closely with its portfolio companies around the world to identify and in-license value-added and differentiated speciality generics, brands and medical devices to ensure that customers and patient groups alike have access to the medicines they require within their respective territories.